Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.49 which represents a decrease of $-0.11 or -0.51% from the prior close of $21.6. The stock opened at $21.59 and ...

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Deckers Outdoor Corp ($DECK) stock was up 1.18% on Wednesday after the apparel and footwear retailer received an upgrade from ...

A new year brings new celebrities to try and spot on the streets of Vancouver. Here are the ones you can keep an eye out for ...

For branded drugmakers, the development of a pharmaceutical product approved by the Food and Drug Administration (FDA) all ...

( MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. ...